Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.13 - $2.1 $2,485 - $4,620
2,200 Added 30.56%
9,400 $19,000
Q2 2024

Aug 14, 2024

SELL
$1.28 - $1.57 $6,784 - $8,321
-5,300 Reduced 42.4%
7,200 $10,000
Q1 2024

May 15, 2024

BUY
$1.28 - $1.65 $16,000 - $20,625
12,500 New
12,500 $18,000
Q2 2023

Aug 14, 2023

SELL
$2.09 - $2.43 $6,688 - $7,776
-3,200 Reduced 78.05%
900 $2,000
Q1 2023

May 15, 2023

SELL
$1.95 - $2.54 $23,400 - $30,480
-12,000 Reduced 74.53%
4,100 $8,000
Q4 2022

Feb 14, 2023

BUY
$1.97 - $2.66 $31,717 - $42,826
16,100 New
16,100 $33,000

Others Institutions Holding MNOV

About MEDICINOVA INC


  • Ticker MNOV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,046,200
  • Market Cap $106M
  • Description
  • MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...
More about MNOV
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.